Australia Partners with OXB to Boost Gene Therapy Manufacturing
澳洲與 OXB 合作，提升基因治療製造能力
On March 18, 2026, the biotechnology world saw a major development as Oxford Biomedica (OXB), a global leader in cell and gene therapy, announced a five-year partnership with Australia’s Viral Vector Manufacturing Facility (VVMF).
2026年3月18日，生物技術界迎來一項重大發展。
This agreement is a significant step forward for the medical sector in the Asia-Pacific (APAC) region.
全球細胞與基因治療領域的領導者牛津生物醫藥（Oxford Biomedica，簡稱OXB）宣布與澳洲病毒載體製造設施（VVMF）建立為期五年的合作夥伴關係。
Under the deal, VVMF gains access to OXB’s proprietary inAAVate™ manufacturing platform, with the option to utilize the renowned LentiVector® technology in the future.
此協議對亞太地區（APAC）的醫療產業而言，是邁向重要里程碑（ㄇㄧˊㄌㄧˇㄅㄟ）的一步。
For VVMF, this collaboration is essential to accelerate its commercial readiness and bring advanced viral-vector manufacturing capabilities to Australia.
根據該協議，VVMF 將獲得使用 OXB 專有的 inAAVate™ 製造平台的權限，並有權在未來選擇使用知名的 LentiVector® 技術。
Meanwhile, for the UK-based OXB, the partnership serves as a strategic launchpad to expand its reach across the growing APAC market.
對 VVMF 而言，此合作對於加速其商業化準備，並將先進的病毒載體製造能力引入澳洲至關重要（ㄓˋㄍㄨㄢㄓㄨㄥㄧㄠˋ）。
By establishing Australia as a regional hub for high-quality, scalable manufacturing, this agreement aims to reduce development risks and shorten timelines for companies creating life-saving therapies.
同時，對於總部位於英國的 OXB 來說，該夥伴關係亦是其擴展亞太市場版圖的戰略跳板。
This move highlights the rising global demand for specialized manufacturing services and reinforces Australia's growing role in the international advanced therapeutics ecosystem.
透過將澳洲打造為高品質、可擴展製造的區域樞紐，此協議旨在降低開發風險，並縮短各公司研發救命療法所需的時程。
